Clinicopathological correlates in frontotemporal lobar degeneration: motor neuron disease spectrum

Álvaro Carbayo,Sergi Borrego-Écija,Janina Turon-Sans,Elena Cortés-Vicente,Laura Molina-Porcel,Jordi Gascón-Bayarri,Miguel Ángel Rubio,Mónica Povedano,Josep Gámez,Javier Sotoca,Raúl Juntas-Morales,Miriam Almendrote,Marta Marquié,Raquel Sánchez-Valle,Ignacio Illán-Gala,Oriol Dols-Icardo,Sara Rubio-Guerra,Sara Bernal,Marta Caballero-Ávila,Ana Vesperinas,Ellen Gelpi,Ricard Rojas-García

DOI: https://doi.org/10.1093/brain/awae011

IF: 14.5

2024-01-18

Brain

Abstract:Amyotrophic lateral sclerosis (ALS) is a devastating motor neuron disease (MND) that shares a common clinical, genetic and pathologic spectrum with frontotemporal dementia (FTD). It is highly heterogeneous in its presentation and features. Up to 50% of patients with MND develop cognitive-behavioural symptoms during the course of the disease, meeting criteria for FTD in 10-15% of cases. In the absence of a precise biomarker, neuropathology is still a valuable tool to understand disease nosology, reach a definite diagnostic confirmation and help define specific subgroups of patients with common phenotypic, genetic and biomarker profiles. However, few neuropathological series have been published, and the frequency of FTLD in MND is difficult to estimate. In this work we describe a large clinicopathologic series of MND, analysing the frequency of concurrent FTLD changes and trying to define specific subgroups of patients based on their clinical, genetic and pathological characteristics. We performed an observational, retrospective, multi-centre case study. We included all cases meeting neuropathological criteria for MND from the Neurological Tissue Bank of the FRCB-IDIBAPS-Hospital Clínic Barcelona Biobank between 1994 and 2022, regardless of their last clinical diagnosis. While brain donation is encouraged in all patients, it is performed in very few, and representativeness of the cohort might not be precise for all patients with MND. We retrospectively reviewed clinical and neuropathological data, and describe the main clinical, genetic and pathogenic features, comparing neuropathologic groups between MND with and without FTLD changes and aiming to define specific subgroups. We included brain samples from 124 patients, 44 of whom (35.5%) had FTLD neuropathologic features (i.e. FTLD-MND). Pathologic TDP-43 aggregates were present in 93.6% of the cohort and were more extensive (higher Brettschneider stage) in those with concurrent FTLD ( p < 0.001). Motor symptom onset was more frequent in the bulbar region in FTLD-MND cases than in those with isolated MND ( p = 0.023), with no differences in survival. We observed a better clinicopathological correlation in the MND group than in the FTLD-MND group (93.8% vs 61.4%; p < 0.001). Pathogenic genetic variants were more common in the FTLD-MND group, especially C9orf72. We describe a frequency of FTLD of 35.5% in our series of neuropathologically confirmed cases of MND. The FTLD-MND spectrum is highly heterogeneous in all aspects, especially in patients with FTLD, in whom it is particularly difficult to define specific subgroups. In the absence of definite biomarkers, neuropathology remains a valuable tool for a definite diagnosis, increasing our knowledge in disease nosology.

neurosciences,clinical neurology

What problem does this paper attempt to address?

The aim of this paper is to explore the clinico-pathological association between amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD), and to attempt to define specific patient subgroups based on clinical, genetic, and pathological characteristics. Specifically, the study describes a clinico-pathological series of a group of motor neuron disease (MND) patients confirmed by neuropathology, analyzes the frequency of concurrent FTLD changes, and attempts to define specific patient subgroups based on these characteristics. In the absence of precise biomarkers, neuropathology remains an important tool for understanding disease classification, confirming diagnoses, and helping to define specific patient subgroups with common phenotypic, genetic, and biomarker characteristics. The study found that among the 124 patients analyzed, 35.5% of the cases exhibited neuropathological features of FTLD. Additionally, the study compared the main clinical, genetic, and pathological characteristics between the MND and FTLD-MND groups and discussed the clinico-pathological correlations.